Maria Morritti

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors

Barbara Pasculli, Raffaela Barbano, Andrea Fontana et al. · Frontiers in Oncology · 2020 · 55 citations · Full text

Medicine, Cancer Biology, Oncology +17

Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients

Raffaela Barbano, Barbara Pasculli, Michelina Rendina et al. · Scientific Reports · 2017 · 53 citations · Full text

Medicine, Molecular Biology, Oncology +17

Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients

Paola Parrella, Raffaela Barbano, Barbara Pasculli et al. · Molecular Cancer · 2014 · 50 citations · Full text

Medicine, Cancer Biology, Oncology +17

Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel

Barbara Pasculli, Raffaela Barbano, Michelina Rendina et al. · Scientific Reports · 2019 · 41 citations · Full text

Medicine, Molecular Medicine, Oncology +15